Testing a new drug (GT-02287) for Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 30–85 years old
- Diagnosed with Parkinson's disease within the last 7 years
- Your symptoms must be mild to moderate (Hoehn & Yahr stages 1–3)
- No severe movement problems or side effects from Parkinson's medications
- You must be willing to have a blood sample taken for genetic testing related to Parkinson's
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This trial tests an investigational drug called IPS101A in people with advanced Parkinson's disease. It aims to see if the drug is safe and how well it works when standard treatments are no longer enough.
This trial tests a new tablet (VG081821AC) for people with early-to-mid-stage Parkinson's disease who have not recently used levodopa. The goal is to see if it can improve movement symptoms safely.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.